tradingkey.logo
tradingkey.logo
Buscar

Grail Inc

GRAL
Añadir a la lista de seguimiento
65.145USD
-1.425-2.14%
Horarios del mercado ETCotizaciones retrasadas 15 min
2.68BCap. mercado
PérdidaP/E TTM

Más Datos de Grail Inc Compañía

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Información de Grail Inc

Símbolo de cotizaciónGRAL
Nombre de la empresaGrail Inc
Fecha de salida a bolsaJun 12, 2024
Director ejecutivoRagusa (Robert)
Número de empleados1000
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección1525 O'brien Drive
CiudadMENLO PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94025
Teléfono18336942553
Sitio Webhttps://grail.com/
Símbolo de cotizaciónGRAL
Fecha de salida a bolsaJun 12, 2024
Director ejecutivoRagusa (Robert)

Ejecutivos de Grail Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
36.42K
+15.08%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
33.88K
+16.21%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
21.92K
+25.05%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
36.42K
+15.08%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
33.88K
+16.21%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
21.92K
+25.05%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Grail Inc?

Los cinco principales accionistas de Grail Inc son: Mr. Aaron Freidin

¿Cuántas instituciones poseen acciones de Grail Inc (GRAL)?

A fecha de 2026Q1, 1071 instituciones poseen acciones de Grail Inc, con un valor de mercado combinado de aproximadamente 33.74M, lo que representa el 78.63% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1763044.00.

¿Cuál es la mayor fuente de ganancias de Grail Inc?

El 2026Q1, el segmento empresarial Screening generó la ganancia más alta para Grail Inc, ascendiendo a 138.60M y representando el 94.18% de la ganancia total.
KeyAI